Group 1 - The article discusses the challenges faced by Pacira BioSciences, Inc. (NASDAQ: PCRX) that have negatively impacted its share price [2] - The investment group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts, buy and sell ratings, product sales forecasts, and financial analyses [2] - The author, Edmund Ingham, has extensive experience in biotech consulting and has prepared detailed reports on over 1,000 companies in the sector [2] Group 2 - The article indicates that the author may initiate a long position in PCRX within the next 72 hours, suggesting potential interest in the stock [3] - There is a disclaimer stating that past performance does not guarantee future results, emphasizing the speculative nature of investments in the biotech sector [4]

-- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three candidates to stand for election to the Pacira Board of Directors (the “Board”) at the Company’s 2025 Annual Meeting of Stockholders. Pacira issued the follo ...

NEW YORK, March 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pacira-biosciences-inc-lawsu ...

Yes, the market has certainly seen its share of volatility recently. It’s led to some treacherous slides in equity prices. It seems that the high beta names are really getting slapped down. In most cases, the mega caps have stood in relatively well. Tuesday’s move to the 200-day on the S&P 500 brought out the bargain shoppers too. Many stocks managed to push into positive territory.On a bounce from those lows, resist the urge to buy everything that moves. Rather, look for stocks with strong earnings trends ...

NEW YORK, March 4, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period"), of the important March 14, 2025 lead plaintiff deadline.So what: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.What to d ...

NEW YORK, March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pacira-biosciences-inc-loss-submission-form/?id=132953&from=4 CLASS PERIOD: Augu ...

Core Insights - Pacira BioSciences reported fourth-quarter 2024 adjusted earnings of 91 cents per share, exceeding the Zacks Consensus Estimate of 86 cents and up from 89 cents in the same quarter last year [1][2] - Total revenues for the fourth quarter reached $187.3 million, a 3% increase year over year, but slightly missed the Zacks Consensus Estimate by 0.03% [2][10] Revenue Breakdown - The company's revenue primarily comes from product sales, specifically from its three marketed drugs: Exparel, Zilretta, and iovera. No royalty revenues were recognized in the fourth quarter [3] - Exparel's net product sales were $147.7 million, a 3% increase from the previous year, surpassing the Zacks Consensus Estimate of $145.3 million [4] - Zilretta's net product sales reached $33.1 million, up 15% year over year, exceeding the Zacks Consensus Estimate of $30.7 million [6] - iovera's net product sales were $6.5 million, a 7% increase from the year-ago quarter, slightly beating the Zacks Consensus Estimate of $6.4 million [7] Expense Analysis - Research and development (R&D) expenses (excluding stock-based compensation) were $22 million, a 33% increase from the previous year due to higher product development and clinical study costs [8] - Selling, general and administrative (SG&A) expenses (excluding stock-based compensation) totaled $70.6 million, a 23% increase year over year, driven by investments in commercial and market access organizations [9] Financial Performance - For the full year 2024, Pacira recorded total revenues of $701 million, a 4% increase from 2023, but slightly below the Zacks Consensus Estimate of $701.9 million [10] - Adjusted earnings for 2024 were $3.20 per share, matching the Zacks Consensus Estimate and up from $2.81 in 2023 [10] Future Guidance - For 2025, Pacira expects total revenues to be in the range of $725-$765 million, with an adjusted gross margin projected between 76% and 78% [11] - Adjusted R&D expenses are anticipated to be between $90 million and $105 million, while adjusted SG&A expenses are expected to range from $290 million to $320 million [11] Recent Developments - The FDA approved a new Smart Tip for the iovera system to manage chronic low back pain, and Pacira secured a patent protecting Exparel's chemical composition until 2044 [12] - New phase I data for PCRX-201 showed improvement in knee pain and function for at least two years, with a favorable safety profile [13]

Financial Data and Key Metrics Changes - The company reported record revenues of $701 million for 2024, at the high end of the guided range [7] - Non-GAAP gross margin for Q4 was 79%, driven by improved margins for EXPAREL and ZILRETTA [46] - Adjusted EBITDA for the quarter was $62.5 million, indicating strong operational performance [46] Business Line Data and Key Metrics Changes - EXPAREL sales increased to $147.7 million in Q4 2024 from $143.9 million in Q4 2023 [45] - ZILRETTA sales rose to $33.1 million in Q4 2024 compared to $28.7 million in Q4 2023 [45] - Iovera sales were $6.5 million in Q4 2024, up from $6.0 million in Q4 2023 [45] Market Data and Key Metrics Changes - The NOPAIN Act now provides a reimbursement pathway for 18 million outpatient surgical procedures, with 6 million under CMS coverage and 12 million under commercial coverage [13] - The company has seen commercial payers adopting NOPAIN-like policies, doubling the previous commercial coverage map to approximately 40 million covered lives [17][18] Company Strategy and Development Direction - The company is focused on executing its 5/30 strategy, aiming for double-digit CAGR in product revenues over the next five years and expanding its innovative pipeline [9][11] - The acquisition of GQ Bio aligns with the 5/30 strategy, adding a high-capacity local delivery platform for genetic medicines [30][31] - The company plans to establish at least five clinical or commercial partnerships by 2030 to enhance its market presence [41] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early signs of progress with the NOPAIN initiative, although they acknowledged that customer adoption will take time [62][63] - The company anticipates a more meaningful uptick in utilization and reimbursement in the second half of 2025 [51][80] - Management emphasized a disciplined approach to capital allocation, balancing growth investments with shareholder returns [49][74] Other Important Information - The company exited Q4 2024 with $485 million in cash and investments, positioning it well for future growth [47] - The board has undergone significant refreshment, reducing the average tenure of directors to less than five years [43] Q&A Session Summary Question: Can you discuss the assumptions for NOPAIN and the potential impediments to rapid uptake? - Management indicated that it will take time for customers to gain traction with NOPAIN, with early signs of progress being encouraging [62][63] Question: Are you seeing successful reimbursement and penetration into new accounts? - Management noted that while it is early days, they are seeing good traction and some commercial payer wins [66][68] Question: What is the company's approach to capital allocation given the growth potential? - Management emphasized a disciplined approach to capital allocation, focusing on funding current operations and innovation while managing the balance sheet [74] Question: Can you provide insight into the relative contributions of the product portfolio for 2025? - Management expects EXPAREL to remain the flagship product, with plans to support ZILRETTA and iovera as well [78] Question: What are the implications of the competitive landscape for the 5/30 growth strategy? - Management expressed confidence that there will not be a risk of generic launches in the near future, supporting their growth projections [82]

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2024 Results Conference Call February 27, 2025 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Shawn Cross - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Gregory Renza - RBC Capital Markets Gary Nachman - Raymond James Hardik Parikh - JPMorgan Operator Good day, and thank you for standing by. Welcome to the Pacira BioSciences Fourth Quarter 2024 Conference Call. [Opera ...

Core Insights - Pacira (PCRX) reported revenue of $187.25 million for the quarter ended December 2024, reflecting a 3.3% increase year-over-year, with EPS at $0.91 compared to $0.89 in the same quarter last year [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $187.31 million, resulting in a surprise of -0.03%, while the EPS exceeded the consensus estimate of $0.86 by 5.81% [1] Revenue Breakdown - Net product sales for iovera were $6.45 million, surpassing the estimated $6.36 million, marking a 6.9% increase year-over-year [4] - Net product sales for EXPAREL reached $147.68 million, exceeding the average estimate of $145.33 million, representing a 2.6% year-over-year growth [4] - Total net product sales amounted to $187.25 million, compared to the average estimate of $183.38 million, indicating a 4.2% year-over-year increase [4] - Net product sales for ZILRETTA were $33.12 million, exceeding the estimated $30.72 million, with a year-over-year change of 15.4% [4] Stock Performance - Over the past month, Pacira's shares have returned -2.1%, slightly better than the Zacks S&P 500 composite's -2.2% change [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), suggesting potential outperformance against the broader market in the near term [3]